Cargando…

Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study

BACKGROUND: This study in patients with rheumatoid arthritis (RA) treated with infliximab describes prospectively the course of (anti)infliximab levels within an infusioncycle to assess at what moment patients develop low/no infliximab trough levels and/or detectable anti-infliximab levels. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	van den Bemt, Bart JF, den Broeder, Alfons A, Wolbink, GJ, Hekster, Yechiel A, van Riel, Piet LCM, Benraad, Bart, van den Hoogen, Frank HJ
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3034722/ https://www.ncbi.nlm.nih.gov/pubmed/21232150 http://dx.doi.org/10.1186/1471-2474-12-12

Ejemplares similares

Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
por: van der Maas, Aatke, et al.
Publicado: (2012)

Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study
por: den Broeder, Alfons A, et al.
Publicado: (2013)

Time to achieve remission determines time to be in remission
por: Schipper, Lydia G, et al.
Publicado: (2010)

Pharmacokinetic boosting to enable a once-daily reduced dose of tofacitinib in patients with rheumatoid arthritis and psoriatic arthritis (the PRACTICAL study)
por: van der Togt, Céleste J.T., et al.
Publicado: (2022)

DAS28: a useful instrument to monitor infliximab treatment in patients with rheumatoid arthritis
por: van Riel, Piet LCM, et al.
Publicado: (2005)

Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial
por: den Broeder, Alfons A., et al.
Publicado: (2017)

Support needs for medication use and the suitability of eHealth technologies to address these needs: a focus group study of older patients with rheumatoid arthritis
por: Mathijssen, Elke GE, et al.
Publicado: (2018)

Perceived need to take medication is associated with medication non-adherence in patients with rheumatoid arthritis
por: Zwikker, Hanneke E, et al.
Publicado: (2014)

The pharmacological and clinical aspects behind dose loading of biological disease modifying anti-rheumatic drugs (bDMARDs) in auto-immune rheumatic diseases (AIRDs): rationale and systematic narrative review of clinical evidence
por: Geurts-Voerman, Gerlienke E., et al.
Publicado: (2020)

Humoral response to coronavirus disease-19 vaccines is dependent on dosage and timing of rituximab in patients with rheumatoid arthritis
por: van der Togt, Céleste J T, et al.
Publicado: (2022)

Seroconversion after a third COVID-19 vaccine is affected by rituximab dose but persistence is not in patients with rheumatoid arthritis
por: van der Togt, Céleste J T, et al.
Publicado: (2022)

Age-Related Health Hazards in Old Patients with First-Time Referral to a Rheumatologist: A Descriptive Study
por: van Lankveld, W., et al.
Publicado: (2011)

Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial
por: Wientjes, Maike H. M., et al.
Publicado: (2021)

Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial
por: van Herwaarden, Noortje, et al.
Publicado: (2015)

Prediction of response to anti-TNF treatment using laboratory biomarkers in patients with rheumatoid arthritis: a systematic review
por: Wientjes, Maike H M, et al.
Publicado: (2022)

Halfway Houses
por: Mountney, George
Publicado: (1970)

(Dis)agreement of polymyalgia rheumatica relapse criteria, and prediction of relapse in a retrospective cohort
por: Bolhuis, Thomas E., et al.
Publicado: (2022)

Psychiatric Halfway Hostels
por: Clifton, E.
Publicado: (1962)

Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study
por: Michielsens, Celia A J, et al.
Publicado: (2021)

Even low alcohol concentrations affect obstacle avoidance reactions in healthy senior individuals
por: Hegeman, Judith, et al.
Publicado: (2010)

Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry
por: Vermeer, Marloes, et al.
Publicado: (2013)

Exploring healthcare professionals’ knowledge, attitudes and experiences of shared decision making in rheumatology
por: Mathijssen, Elke G E, et al.
Publicado: (2020)

A Serious Puzzle Game to Enhance Adherence to Antirheumatic Drugs in Patients With Rheumatoid Arthritis: Systematic Development Using Intervention Mapping
por: Pouls, Bart PH, et al.
Publicado: (2022)

Digital vasculitis in a patient with rheumatoid arthritis: good response on anti-TNF blockade
por: van den Hoogen, F, et al.
Publicado: (2001)

Outcome measures in inflammatory rheumatic diseases
por: Fransen, Jaap, et al.
Publicado: (2009)

Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis
por: Tweehuysen, Lieke, et al.
Publicado: (2018)

Little Evidence for Usefulness of Biomarkers for Predicting Successful Dose Reduction or Discontinuation of a Biologic Agent in Rheumatoid Arthritis: A Systematic Review
por: Tweehuysen, Lieke, et al.
Publicado: (2017)

European Society of Clinical Pharmacy definition of the term clinical pharmacy and its relationship to pharmaceutical care: a position paper
por: Dreischulte, Tobias, et al.
Publicado: (2022)

Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA)
por: Mulder, Michelle L. M., et al.
Publicado: (2020)

Psychiatric Halfway Hostels in England: II
por: Huseth, Brete
Publicado: (1962)

Psychiatric Halfway Hostels in England: I
por: Huseth, Brete
Publicado: (1962)

Meeting the research(er) and the researched halfway
por: Letiche, Hugo, et al.
Publicado: (2022)

What causes a small increase in radiographic progression in rheumatoid arthritis patients tapering TNF inhibitors?
por: Bouman, Chantal A M, et al.
Publicado: (2017)

IceCube construction reaches halfway point
Publicado: (2008)

Robert Spitzer's legacy: agreement is halfway to truth
por: Tyrer, Peter
Publicado: (2018)

Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study
por: van der Togt, Céleste J T, et al.
Publicado: (2023)

(Ultra-)low dosing of rituximab in rheumatoid arthritis: chances and challenges
por: den Broeder, Alfons A, et al.
Publicado: (2021)

Pharmacogenetic-guided cannabis usage in the community pharmacy: evaluation of a pilot program
por: Papastergiou, John, et al.
Publicado: (2020)

Discontinuation of biologic DMARDs in non-systemic JIA patients: a scoping review of relapse rates and associated factors
por: Gieling, Job, et al.
Publicado: (2022)

PolyMyalgia Rheumatica treatment with Methotrexate in Optimal Dose in an Early disease phase (PMR MODE): study protocol for a multicenter double-blind placebo controlled trial
por: Marsman, Diane E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_e6jqt3jcmi4nf4dbr5p2qqmg2j